- Home
- JBGS vs MYGN Comparison
JBGS vs MYGN Comparison
Compare JBGS & MYGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- JBGS
- MYGN
- Stock Information
- Founded
- JBGS 2016
- MYGN 1991
- Country
- JBGS United States
- MYGN United States
- Employees
- JBGS N/A
- MYGN N/A
- Industry
- JBGS Real Estate Investment Trusts
- MYGN Biotechnology: In Vitro & In Vivo Diagnostic Substances
- Sector
- JBGS Real Estate
- MYGN Health Care
- Exchange
- JBGS Nasdaq
- MYGN Nasdaq
- Market Cap
- JBGS 1.3B
- MYGN 1.3B
- IPO Year
- JBGS 2017
- MYGN 1995
- Fundamental
- Price
- JBGS $16.12
- MYGN $8.87
- Analyst Decision
- JBGS Sell
- MYGN Hold
- Analyst Count
- JBGS 2
- MYGN 15
- Target Price
- JBGS $16.00
- MYGN $21.37
- AVG Volume (30 Days)
- JBGS 1.2M
- MYGN 894.0K
- Earning Date
- JBGS 04-29-2025
- MYGN 05-06-2025
- Dividend Yield
- JBGS 4.32%
- MYGN N/A
- EPS Growth
- JBGS N/A
- MYGN N/A
- EPS
- JBGS N/A
- MYGN N/A
- Revenue
- JBGS $546,890,000.00
- MYGN $837,600,000.00
- Revenue This Year
- JBGS N/A
- MYGN $2.97
- Revenue Next Year
- JBGS $7.15
- MYGN $8.37
- P/E Ratio
- JBGS N/A
- MYGN N/A
- Revenue Growth
- JBGS N/A
- MYGN 11.21
- 52 Week Low
- JBGS $13.65
- MYGN $8.53
- 52 Week High
- JBGS $18.86
- MYGN $29.30
- Technical
- Relative Strength Index (RSI)
- JBGS 60.29
- MYGN 27.63
- Support Level
- JBGS $15.74
- MYGN $9.68
- Resistance Level
- JBGS $16.12
- MYGN $10.30
- Average True Range (ATR)
- JBGS 0.51
- MYGN 0.52
- MACD
- JBGS 0.11
- MYGN -0.01
- Stochastic Oscillator
- JBGS 93.11
- MYGN 11.59
About JBGS JBG SMITH Properties
JBG SMITH Properties is a real estate investment trust based in the United States. It owns, operates, invests in and develops real estate assets concentrated in urban infill submarkets in and around Washington, DC. In addition, the company also provides fee-based real estate services to the legacy funds through its third-party real estate services business. The operating segments of the company are commercial, multifamily and third-party asset management and real estate services. The company generates majority of its revenue from Commercial segment.
About MYGN Myriad Genetics Inc.
Myriad Genetics is a molecular diagnostics company that provides testing services designed to assess an individual's risk of developing a disease. The firm produces MyRisk, a 48-gene panel with the capability to identify the elevated risk of developing 11 types of cancer. Other diagnostic products include BRACAnalysis CDx, the FDA-approved companion diagnostic for PARP inhibitors; GeneSight, which helps improve responses to psychotropic drugs for patients suffering from depression; and Prequel, a noninvasive prenatal test. Precise Oncology Solutions, launched in 2022, combines Precise Tumor with companion diagnostic and prognostic tests such as MyChoice CDx, Prolaris, and EndoPredict. The firm offers biomarker discovery and companion diagnostic services to pharma and biotech companies.